Compare McKesson Corporation (MCK) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs S&P500 ETF — how do they compare? McKesson Corporation trades at $882.8 (market cap $105.14B), while S&P500 ETF trades at $772.72. The key difference: McKesson Corporation pays a 0.42% dividend while S&P500 ETF pays none, and S&P500 ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.
| MCK | SPY | |
|---|---|---|
Market Cap | $105.14B | — |
Sector | Health | — |
52-Week High | $995.69 | $773.22 |
52-Week Low | $659.01 | $631.99 |
Enterprise Value | $111.67B | — |
Dividend Yield | 0.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $889.01, up 1.04% today, with a bullish technical outlook and strong institutional support. Recent Q1 2027 earnings beat expectations, with EPS of $9.93 versus $9.56, driven by specialty drug growth and oncology performance. Revenue reached $359.05B in 2025, with net income of $3.30B, though margins remain thin. The company raised full-year guidance, reflecting operational momentum.
The stock offers upside to the consensus price target of $990.67, supported by 80% analyst buy ratings. Key risks include reliance on pharmaceutical distribution margins, regulatory pressures, and competitive threats. Earnings consistency and cost discipline are critical for sustaining valuation multiples amid healthcare sector volatility.
SPY, the SPDR S&P 500 ETF Trust, trades at $773.08 with minimal daily change, reflecting stability near record highs. Technical indicators show a bullish trend with strong moving average signals, though oscillators are neutral and RSI levels suggest overbought conditions. The ETF remains a core holding for broad U.S. equity exposure, with a dividend scheduled for July 2026. Market sentiment is mixed, balancing optimism from AI-driven gains against concerns over elevated valuations.
The outlook for SPY hinges on sustained earnings growth and macroeconomic factors, with upside potential if corporate profits meet expectations. Risks include high valuation multiples, potential interest rate shifts, and geopolitical tensions. Institutional analysts monitor inflation data and earnings revisions for directional cues, with the ETF's low expense ratio and liquidity supporting its appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
